Recent study shows Livionex Dental Gel offers increased plaque protection

November 17, 2014

Livionex, Inc., a Sillicon Valley life science company focused on biofilms and inflammation, recently released the results of  a double blind clinical trial study on reduction of plaque, gingivitis and gum bleeding.

Livionex, Inc., a Sillicon Valley life science company focused on biofilms and inflammation, recently released the results of  a double blind clinical trial study on reduction of plaque, gingivitis and gum bleeding.

The study was conducted at the Beckman Laser Institute of UC Irvine and compared Livionex Dental Gel to Colgate Total, the leading ADA and FDA approved anti-plaque, anti-gingivitis toothpaste.

The results showed an unprecedented 260% reduction in plaque index, 229% reduction in gingivitis index and a 232% reduction in gum bleeding index as compared to Colgate Total. The results have been published in the journalLasers in Surgery and Medicine.

Related reading: Saliva plays key role in caries prevention

Data from both the US Centers for Disease Control and British Medical Journal show that 90% of adults suffer from gingivitis and 47% of all Americans have periodontitis-both caused by plaque. These numbers imply the failure of traditional toothpaste to reduce plaque, which is an oral biofilm. Livionex Dental Gel technology virtually eliminates plaque through daily brushing without the use of any harsh abrasives, detergents or antimicrobials, which are the mainstays of all current toothpaste products on the market.

Amit Goswamy, the CEO of Livionex, commented, "We are very pleased with the results of the UC Irvine study and the interest it is generating across the industry. The Livionex team is excited that the dental gel will pave the way to combat America's silent epidemic of gingivitis and periodontitis."

The Livionex formulation uses activated Edathamil, a common food preservative, to break up the bond between the plaque biofilm and teeth, thereby interfering with the ability of plaque to stick to teeth. It is also able to reach plaque in gum margins and between teeth. It is this high-risk plaque that has been implicated in gingivitis and periodontitis. Oral diseases like periodontitis have been linked to a variety of systemic disease like cardiac disease, arthritis, diabetes and more.

Trending article: Let's talk about money: The 2014 dental fee survey

Dr. Peter Jacobson, a well-known dental pharmacologist and over-the-counter dental products expert said, "Any product that can improve the effectiveness of tooth brushing at a level demonstrated by Livionex is not only a breakthrough, but can be categorized as a disruptive innovation with major public health implications. It redefines what toothpaste and oral hygiene are all about."

Livionex Inc. was founded in 2009 by Stanford and Berkeley alums with the goal of enhancing the quality and longevity of human life. The company is focused on addressing the role of metal ions in aging and diseases of the human body.